Alpha-1 antitrypsin augmentation therapy

Mark D. Wewers, Ronald Crystal

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions primarily to inhibit neutrophil elastase (NE), and the observation that NE instilled into the lung of experimental animals resulted in emphysema, the concept evolved that the pulmonary manifestations of the disease could be halted by intermittent intravenous infusions of AAT purified from pooled human plasma. Following preliminary clinical studies in the academic community, and then pharmaceutical company development of large scale purification of human AAT, the FDA approved the use of weekly AAT augmentation therapy for AATD following a clinical trial which demonstrated that weekly infusions would raise to normal plasma and lung epithelial fluid levels of AAT in AAT-deficient individuals. The therapy is now used worldwide to treat AATD, the only pulmonary genetic disease with effective therapy for all affected individuals.

Original languageEnglish
Pages (from-to)64-67
Number of pages4
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume10
Issue numberS1
DOIs
Publication statusPublished - 1 Mar 2013
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency
Leukocyte Elastase
Inborn Genetic Diseases
Therapeutics
Lung Diseases
Lung
Emphysema
Intravenous Infusions
Clinical Trials
Liver
Pharmaceutical Preparations
Genes

Keywords

  • Alpha-1 antitrypsin
  • Augmentation therapy
  • Pulmonary genetic disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Alpha-1 antitrypsin augmentation therapy. / Wewers, Mark D.; Crystal, Ronald.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 10, No. S1, 01.03.2013, p. 64-67.

Research output: Contribution to journalReview article

@article{0ad2b3517ebf4812893978c3d1d85fbc,
title = "Alpha-1 antitrypsin augmentation therapy",
abstract = "The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions primarily to inhibit neutrophil elastase (NE), and the observation that NE instilled into the lung of experimental animals resulted in emphysema, the concept evolved that the pulmonary manifestations of the disease could be halted by intermittent intravenous infusions of AAT purified from pooled human plasma. Following preliminary clinical studies in the academic community, and then pharmaceutical company development of large scale purification of human AAT, the FDA approved the use of weekly AAT augmentation therapy for AATD following a clinical trial which demonstrated that weekly infusions would raise to normal plasma and lung epithelial fluid levels of AAT in AAT-deficient individuals. The therapy is now used worldwide to treat AATD, the only pulmonary genetic disease with effective therapy for all affected individuals.",
keywords = "Alpha-1 antitrypsin, Augmentation therapy, Pulmonary genetic disease",
author = "Wewers, {Mark D.} and Ronald Crystal",
year = "2013",
month = "3",
day = "1",
doi = "10.3109/15412555.2013.764402",
language = "English",
volume = "10",
pages = "64--67",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "S1",

}

TY - JOUR

T1 - Alpha-1 antitrypsin augmentation therapy

AU - Wewers, Mark D.

AU - Crystal, Ronald

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions primarily to inhibit neutrophil elastase (NE), and the observation that NE instilled into the lung of experimental animals resulted in emphysema, the concept evolved that the pulmonary manifestations of the disease could be halted by intermittent intravenous infusions of AAT purified from pooled human plasma. Following preliminary clinical studies in the academic community, and then pharmaceutical company development of large scale purification of human AAT, the FDA approved the use of weekly AAT augmentation therapy for AATD following a clinical trial which demonstrated that weekly infusions would raise to normal plasma and lung epithelial fluid levels of AAT in AAT-deficient individuals. The therapy is now used worldwide to treat AATD, the only pulmonary genetic disease with effective therapy for all affected individuals.

AB - The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions primarily to inhibit neutrophil elastase (NE), and the observation that NE instilled into the lung of experimental animals resulted in emphysema, the concept evolved that the pulmonary manifestations of the disease could be halted by intermittent intravenous infusions of AAT purified from pooled human plasma. Following preliminary clinical studies in the academic community, and then pharmaceutical company development of large scale purification of human AAT, the FDA approved the use of weekly AAT augmentation therapy for AATD following a clinical trial which demonstrated that weekly infusions would raise to normal plasma and lung epithelial fluid levels of AAT in AAT-deficient individuals. The therapy is now used worldwide to treat AATD, the only pulmonary genetic disease with effective therapy for all affected individuals.

KW - Alpha-1 antitrypsin

KW - Augmentation therapy

KW - Pulmonary genetic disease

UR - http://www.scopus.com/inward/record.url?scp=84875668547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875668547&partnerID=8YFLogxK

U2 - 10.3109/15412555.2013.764402

DO - 10.3109/15412555.2013.764402

M3 - Review article

C2 - 23527997

AN - SCOPUS:84875668547

VL - 10

SP - 64

EP - 67

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - S1

ER -